<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758446</url>
  </required_header>
  <id_info>
    <org_study_id>OX914-001</org_study_id>
    <nct_id>NCT00758446</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Cross-over, Allergen Challenge Study to Evaluate the Efficacy, Safety and Tolerability of BLX-028914 in Subjects With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dart NeuroScience, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orexo AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dart NeuroScience, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare
      the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge
      model. BLX-028914, a selective phosphodiesterase-4 (PDE4) inhibitor with a promising safety
      profile,is currently under development for treatment of airway diseases by Orexo AB, Sweden.

      The aim of this study is to compare the effect, safety and tolerability of 14 days treatment
      with BLX-0289014 in patients with SAR in an allergen challenge model versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post allergen challenge; Total Nasal Symptom Score(TNSS)</measure>
    <time_frame>10 minutes after allergen challenge</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLX-028914 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLX-028914 15 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLX-028914</intervention_name>
    <description>50 mg capsules, p.o, daily, 14 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLX-028914</intervention_name>
    <description>15 mg capsules, p.o, daily, 14 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsules, p.o, daily, 14 days</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 50 years of age (inclusive), male or female

          -  Body Mass Index (BMI) between 18 and 28 kg/m2 (inclusive)

          -  History of pollen-induced seasonal allergic rhinitis but otherwise healthy

          -  Positive skin prick test for timothy and/or birch allergen

          -  Sufficient reaction to nasally administered allergen at screening

          -  Signed informed consent obtained

        Exclusion Criteria:

          -  Expected symptoms of seasonal allergic rhinitis during the study period

          -  Asthma

          -  Nasal anatomical deviations, ongoing nasal symptoms, ongoing upper respiratory tract
             infection

          -  Anti-allergy immunotherapy in the previous two years

          -  Extensive use of nasal sprays

          -  Any medication except for contraceptives, during their last five half- lives prior to
             the first treatment period except for occasional OTC analgesics

          -  Ingestion of grapefruit or grapefruit juice or herbal remedies (e.g. St John's-wort)
             that may effect the enzyme CYP3A4

          -  Smoking within 3 months of first treatment period

          -  Clinically significant laboratory findings

          -  Pregnant or breast feeding woman or woman of childbearing potential not using adequate
             birth control

          -  Known hypersensitivity to any constituent of the study medication or placebo

          -  Participation in any other investigational study in the last three months

          -  Subject anticipated not being able to adhere to study plan according to investigator
             judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lennart Greiff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of otorhinolaryngology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of otorhinolaryngology</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

